Seladelpar

CHEMBL230158 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

444.5 g/mol

LogP

5.2

Phase

4

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist under investigation for the treatment of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). By activating PPAR-delta in hepatocytes and cholangiocytes, it modulates bile acid synthesis, reduces hepatic inflammation, and improves metabolic parameters. Clinical trials have demonstrated reductions in alkaline phosphatase and pruritus in PBC patients.

Peso Molecular

444,5000 g/mol

LogP

5,20

TPSA

90,30 Å²

Regra dos 5 de Lipinski

Aprovado

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1

InChI

InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1

Molecular Formula

C21H23F3O5S

HBD / HBA

1 / 9

Ligações Rotacionáveis

11

Átomos Pesados

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist under investigation for the treatment of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). By activating PPAR-delta in hepatocytes and cholangiocytes, it modulates bile acid synthesis, reduces hepatic inflammation, and improves metabolic parameters. Clinical trials have demonstrated reductions in alkaline phosphatase and pruritus in PBC patients.

Yes, Seladelpar is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL230158. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11236126. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Procura informações acessíveis para o paciente?

Seladelpar no PillFYI

Estrutura

Dados Rápidos

Fórmula: C21H23F3O5S
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.